



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

May 25, 2004

FILE COPY

Mr. Charles J. Raubicheck
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, New York 10151

Dear Mr. Raubicheck:

Your petition on behalf of Alphapharm Pty Ltd of Glebe, New South Wales, Australia requesting the Food and Drug Administration to declare that an Abbreviated New Drug Application (ANDA) may be filed for the drug escitalopram in a capsule dosage form, was received by this office on 05/25/2004. It was assigned docket number 2004P-0247 /CP 1 and it was filed on 05/25/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2004P-0247

ACK 1